Loading…
Loading…
RPTX (Repare Therapeutics Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
RPTX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RPTX and 80,000+ other tickers.
See exactly how RPTX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RPTX and 80,000+ other tickers.
Repare Therapeutics Inc. is a precision oncology biopharmaceutical company in the clinical stage, focused on discovering and developing innovative therapies. Operating across Canada and the United States, the company leverages a synthetic lethality approach to identify new treatments. Central to their efforts is the proprietary, genome-wide, and CRISPR-enabled SNIPRx platform, which systematically uncovers and advances highly targeted cancer medicines. These therapies are specifically designed to address genomic instability, particularly related to DNA damage repair mechanisms. Their primary…
Repare Therapeutics Inc. (NASDAQ: RPTX - Get Free Report)'s stock price rose 0.8% on Thursday. The company traded as high as $2.65 and last traded at $2.65. Approximately 1,219,900 shares were traded during trading, an increase of 29% from the average daily volume of 947,968 shares. The stock had previously closed at $2.63. Wall Street
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly “Xeno”) a non-profit biotechnology company, b.
Repare Therapeutics Inc. (NASDAQ: RPTX - Get Free Report)'s stock price rose 0.4% on Wednesday. The stock traded as high as $2.61 and last traded at $2.60. Approximately 426,036 shares changed hands during trading, a decline of 71% from the average daily volume of 1,465,188 shares. The stock had previously closed at $2.59. Analyst Upgrades
Repare Therapeutics Inc. (NASDAQ: RPTX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors acquired 3,187 call options on the company. This is an increase of approximately 407% compared to the typical daily volume of 629 call options. Institutional Trading of Repare Therapeutics A number of institutional investors have recently
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”). “We are pleased to announce this transaction which combines Gilead's leading expertise in oncology research and development with RP-3467, a potential best-in-class.